Intensification Therapy of Mature B-ALL, Burkitt and Burkitt Like and Other High Grade Non-Hodgkin's Lymphoma in Adults

Inclusion Criteria:

• Acute lymphoblastic leukemia of the mature B-cell type (L3-ALL)

• High-grade non-Hodgkin's lymphoma of the following subtypes (WHO classification)

  • Burkitt's lymphoma (including atypical Burkitt's lymphoma)
  • Precursor B-lymphoblastic lymphoma
  • Anaplastic large-cell lymphoma (Ki1+, B-, T- oder Null-cell-type)
  • Mediastinal large B-cell-lymphoma (subtype of diffuse large B-cell lymphoma)
• Age = 18 years
• Patient's Informed Consent

Exclusion Criteria:

• Serious complications caused by leukemia/ lymphoma or by a second illness: e.g.

  • Severe, unmanageable complications such as sepsis, pneumonia with oxygen deficiency,
  • Shock, hemorrhage at the time of diagnosis
  • Renal insufficiency from leukemia/lymphoma-unrelated causes
  • Severe cardiac or hepatic insufficiency
  • Severe obstructive or restrictive lung disease that would compromise patient's treatment with intensified chemotherapy
  • HIV infection
  • Secondary lymphoma following prior chemotherapy/ radiotherapy or an active second malignancy
  • Known severe allergy to foreign proteins
• Cytostatic pretreatment for B-ALL/lymphoma (exceptions: short-term administration of steroids = 7 days, single administration of vincristine or cyclophosphamide, one cycle of CHOP, a single administration in an emergency of other cytostatic agents) for another malignant disease within the last 5 years
• Pregnancy/ nursing period
• Severe psychiatric illness or other circumstances giving ground to the assumption that a patient cannot give his consent to therapy or act co-operatively
• Absence of patient's informed consent
• Participation in another clinical study that would possibly interfere with study therapy